Onset and Duration of Fentanyl
Intravenous fentanyl has an onset of action of approximately 2 minutes and a duration of effect of approximately 30-60 minutes, while intranasal fentanyl has an onset of approximately 5-7 minutes with a similar duration of 1 hour. 1, 2
Route-Specific Pharmacokinetics
Intravenous Administration
- Onset of analgesia: 2 minutes 2
- Time to peak concentration (Tmax): 6 minutes 1
- Duration of effect: Approximately 59 minutes 2
- Transfer half-life to CNS: 4.7-6.6 minutes (extremely rapid blood-brain barrier penetration due to high lipophilicity) 3
Intranasal Administration
- Onset of analgesia: 7 minutes 4, 1
- Time to peak concentration (Tmax): 12-13 minutes 1, 2
- Duration of effect: 56-60 minutes 2
- Bioavailability: 89% 4, 1
- Absorption lag time: Approximately 5 minutes 1
- Dose-dependent duration: Ranges from 120 minutes (75 mcg dose) to 240 minutes (200 mcg dose) 1
Transmucosal Formulations (Oral)
- Onset of analgesia: Within 15 minutes 5
- Time to peak concentration: 20 minutes (range 20-180 minutes) 3
- Bioavailability: 50-90% 3
Transdermal Patches
- Onset: Not suitable for rapid titration 6
- Duration: Constant zero-order release for 2-3 days 3
- Clinical note: Contraindicated for acute or breakthrough pain management 6
Clinical Context from Guidelines
The NCCN guidelines 6 specify that for parenteral fentanyl, the conversion factor from IV morphine varies significantly:
- Single-dose: 10 mg IV morphine ≈ 100 mcg IV fentanyl
- Steady-state (repeated dosing): 10 mg IV morphine ≈ 250 mcg IV fentanyl
This 2.5-fold difference is critical for safe dosing and reflects fentanyl's accumulation with repeated administration.
Pharmacodynamic Considerations
The concentration-analgesia relationship for fentanyl is steep (Hill coefficient 3.5), with a 50% effective concentration of 0.46 ng/mL 1. The analgesic effect lags behind venous concentration by approximately 2.5 minutes, representing the equilibration time between blood and the CNS 1.
Route Selection for Clinical Practice
For breakthrough cancer pain: Rapid-onset fentanyl formulations (intranasal or oral transmucosal) are preferred over immediate-release oral opioids due to their 15-minute onset matching the typical pain episode duration 5. The ASCO guidelines 7 recommend immediate-release opioids at 5-20% of daily morphine equivalent dose for breakthrough pain, though they note insufficient evidence to recommend a specific short-acting opioid.
Critical caveat: The FDA label 8 explicitly contraindicates transdermal fentanyl for labor/delivery analgesia and in nursing mothers due to placental transfer and breast milk excretion. Transdermal fentanyl should only be used in opioid-tolerant patients after pain is controlled with other opioids 6.